flipper, thanks for the detail. I agree the clinicaltrials listing looks like metastatic tumors are in Phase II. That could also explain why a slow pace - it probably is difficult to find patients with i) an inoperable tumor, and ii) no metasteses. Your scenario is the likely one I think.
Try this one on: liver cancer typically presents with many tumors large and small, which if are present following resection, are inoperable (resection only possible once in liver cancer). If this type of patient were allowed, i.e., a patient with cancer isolated to 1 organ, but with multiple tumors, a systemic response of sorts - 'organwide' actually (can you tell I'm not an MD) - could be seen with 1 tumor being injected and then seeing tumors in addition to the injected tumor being shrunk or resolved. I don't know if this type of patient would be classified as having metasteses or not? (Because of the lack of available treatments, I would think MD Anderson is deluged with pancreatic and post-resection liver cancer patients.)
Regardless, I agree evidence that NWBO has an immunotherapy treatment that picks up the biomarkers in vivo and is effective would be ASCO-worthy - to my knowledge it would be a first in human medicine.
News 
Market Data 
Discover 
